Video

Dr. LoRusso on Personalized Medicine for Melanoma

Author(s):

Patricia M. LoRusso, DO

In Partnership With:

Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

All the patients on the trial have progressed on immunotherapy and are now in need of additional treatment. Currently, there are no targeted therapies approved by the FDA for this subset of patients.

By using genotyping, individualized treatments are selected for each of theses patient based on their tumor, explains LoRusso. This approach is predicted to be more effective than the standard of care.

Related Videos
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Phillip Phillip, MD
Katherine L. Nathanson, MD
PEDRO BARATA, MD
Anthony M. Hunter, MD
Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University
John K. Lee, MD, PhD, associate professor-in-residence, Division of Hematology/Oncology, Department of Medicine; the Institute for Urologic Oncology, Department of Urology, the David Geffen School of Medicine, UCLA Heath
Tae Min Kim, MD, PhD
Whitney Goldsberry, MD
Syed Abbas Ali, MBBS
Related Content
The FDA approved sotorasib (Lumakras) with panitumumab (Vectibix) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
January 16th 2025

FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Early-Stage CTCL | Image Credit: ©ReisMedia - stock.adobe.com
January 14th 2025

Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Erica L. Mayer, MD, MPH
January 13th 2025

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

Basal Cell Carcinoma | Maris– stock.adobe.com
January 8th 2025

Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission